ライフサイエンスコーパス: peripheral T-cell lymphoma

1 f SYK, and it is believed to be the cause of peripheral T cell lymphoma.

2 transplant lymphoproliferative disorder, and peripheral T cell lymphoma.

3 (ALCL) is the most common type of pediatric peripheral T-cell lymphoma.

4 ted T-cell lymphoma (EATL) is a rare type of peripheral T-cell lymphoma.

5 stigation for the treatment of patients with peripheral T-cell lymphoma.

6 with large-cell transformation), and two had peripheral T-cell lymphoma.

7 ed adult T-cell leukaemia-lymphoma and other peripheral T-cell lymphomas.

8 e T-cell leukemia (T-ALL) and in a subset of peripheral T-cell lymphomas.

9 of lymphomas, which included a large set of peripheral T-cell lymphomas.

10 a, adult T-cell leukemia/lymphoma, and other peripheral T-cell lymphomas.

11 n TEL-FGFR3 associated with t(4;12)(p16;p13) peripheral T-cell lymphomas.

12 anaplastic large-cell lymphomas, 2/12 nodal peripheral T-cell lymphomas, 1/3 CD8+ cutaneous T-cell l

13 ated HD (100%) and EBV+ Malaysian and Danish peripheral T-cell lymphomas (100%, 61% respectively), bu

14 as (15.3%), classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.3%) of which angioimmunob

15 ;q22) translocation was found in a subset of peripheral T cell lymphomas and was shown to result in a

16 le the diagnosis of unusual entities such as peripheral T-cell lymphomas and Hodgkin disease in patie

17 CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF

18 s that can easily be mistaken for intestinal peripheral T-cell lymphoma, and lead to aggressive thera

19 Peripheral T-cell lymphomas are an uncommon and heteroge

20 The genetics of peripheral T-cell lymphomas are poorly understood.

21 is study was to compare in a large series of peripheral T cell lymphoma, as a model of diffuse diseas

22 FGFR3 TDII-induced pre-B cell lymphoma, or a peripheral T-cell lymphoma associated TEL-FGFR3 fusion-i

23 ve been approved for relapsed and refractory peripheral T-cell lymphomas based on their activity, alt

24 status (PS) >/= 2; the Prognostic Index for Peripheral T-Cell Lymphoma, comprising: age >/= 60 years

25 e animal model may help our understanding of peripheral T-cell lymphoma development.

26 c T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities.

27 Two of three peripheral T-cell lymphomas--including one anaplastic la

28 th fulminant hepatic failure from an unusual peripheral T cell lymphoma involving the liver and splee

29 antigen expression in the classification of peripheral T-cell lymphomas is still unclear.

30 xate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective s

31 astic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence.

32 ogies included DLBCL (n = 21), MCL (n = 13), peripheral T-cell lymphoma (n = 8), transformed follicul

33 ymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphoma

34 nts (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 a

35 le to successfully separate ALK(-) ALCL from peripheral T-cell lymphoma not otherwise specified, with

36 s, 9 angioimmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not otherwise specified (PTC

37 mphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTC

38 Compared with peripheral T-cell lymphoma, not otherwise specified and

39 The most common PTCLs, peripheral T-cell lymphoma, not otherwise specified, ang

40 Peripheral T-cell lymphoma, not otherwise specified, is

41 phoma, including eight children with typical peripheral T-cell lymphomas of various types.

42 ted by T-cell responses were associated with peripheral T-cell lymphoma (OR = 2.14, 95% CI: 1.35, 3.3

43 There was an increased OR for peripheral T-cell lymphoma (OR = 2.42, 95% CI, 1.24-4.72

44 A frame-shift ATM mutation was found in one peripheral T cell lymphoma patient.

45 Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma presenting mostly in children

46 The International Peripheral T-cell Lymphoma Project is a collaborative ef

47 The International Peripheral T-Cell Lymphoma Project was undertaken to bet

48 A newly developed model of peripheral T cell lymphoma (PTCL) using the ITK-SYK fusi

49 n addition, a significant subset of cases of peripheral T cell lymphoma (PTCL), 39 of 81 cases (48%),

50 lymphocytic leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EmuSRalpha-tTA;Tet

51 Peripheral T-cell lymphoma (PTCL) and natural killer/T-c

52 ion of Lin28b in vivo leads to an aggressive peripheral T-cell lymphoma (PTCL) characterized by wides

53 Peripheral T-cell lymphoma (PTCL) encompasses a heteroge

54 Peripheral T-cell lymphoma (PTCL) is a heterogeneous gro

55 Peripheral T-cell lymphoma (PTCL) is a poor prognosis su

56 Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneo

57 Peripheral T-cell lymphoma (PTCL) is often challenging t

58 T-cell clonality of peripheral T-cell lymphoma (PTCL) is routinely evaluated

59 homa (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL).

60 , but very little is known about the risk in peripheral T-cell lymphoma (PTCL).

61 ntuximab vedotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).

62 T) that mimics inflammatory bowel disease or peripheral T-cell lymphoma (PTCL).

63 psin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

64 a collaborative effort to better understand peripheral T-cell lymphoma (PTCL).

65 nal Prognostic Factor Index in patients with peripheral T-cell lymphoma (PTCL).

66 12), mantle cell lymphoma (MCL; n = 7), and peripheral T-cell lymphoma (PTCL; n = 5).

67 Peripheral T-cell lymphomas (PTCL) are a group of rare m

68 The peripheral T-cell lymphomas (PTCL) are a heterogeneous g

69 Peripheral T-cell lymphomas (PTCL) are aggressive diseas

70 Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens suc

71 Peripheral T cell lymphomas (PTCLs) are a heterogeneous

72 Peripheral T cell lymphomas (PTCLs) are a heterogeneous

73 Peripheral T cell lymphomas (PTCLs) are heterogeneous ne

74 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous

75 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous

76 Peripheral T-cell lymphomas (PTCLs) are aggressive malig

77 Peripheral T-cell lymphomas (PTCLs) are rare lymphomas w

78 The peripheral T-cell lymphomas (PTCLs) encompass a heteroge

79 Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clin

80 Peripheral T-cell lymphomas (PTCLs) represent a diverse

81 Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to co

82 cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understo

83 dotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising effic

84 nt's role remain elusive for the most common peripheral T-cell lymphomas (PTCLs).

85 in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs).

86 e differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwi

87 anned subset analysis included patients with peripheral T-cell lymphomas (PTCLs; n = 35), specificall

88 t T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dos

89 arge B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively.

90 absence of a mass lesion or lymphadenopathy, peripheral T cell lymphoma should be included in the dif

91 One hundred six patients with peripheral T cell lymphoma, staged with PET/CT, were enr

92 ive adult T-cell leukaemia-lymphoma or other peripheral T-cell lymphoma subtypes, and at least one pr

93 In this model of mature peripheral T cell lymphomas, the cell of origin was a ma

94 In patients with Hodgkin's lymphoma and peripheral T-cell lymphoma, treatment with bendamustine

95 a had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete

96 Here, we investigate the origin of peripheral T cell lymphomas using mice in which Snf5, a

97 Historically, peripheral T-cell lymphomas were treated with strategies

98 ho had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous dise

99 ll lymphoma (AITL) is the second most common peripheral T-cell lymphoma with unusual clinical and pat

100 T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis.

101 motherapy because of an initial diagnosis of peripheral T-cell lymphoma, with little or no response,